LLY
776.45
-2.39%↓
JNJ
152.33
+0.12%↑
ABBV
182.26
-2.5%↓
NVO
68.53
+1.17%↑
UNH
308.74
+2.11%↑
LLY
776.45
-2.39%↓
JNJ
152.33
+0.12%↑
ABBV
182.26
-2.5%↓
NVO
68.53
+1.17%↑
UNH
308.74
+2.11%↑
LLY
776.45
-2.39%↓
JNJ
152.33
+0.12%↑
ABBV
182.26
-2.5%↓
NVO
68.53
+1.17%↑
UNH
308.74
+2.11%↑
LLY
776.45
-2.39%↓
JNJ
152.33
+0.12%↑
ABBV
182.26
-2.5%↓
NVO
68.53
+1.17%↑
UNH
308.74
+2.11%↑
LLY
776.45
-2.39%↓
JNJ
152.33
+0.12%↑
ABBV
182.26
-2.5%↓
NVO
68.53
+1.17%↑
UNH
308.74
+2.11%↑
24h
Current
Min
4.03
Max
4.28
Income | 12M -52M |
---|---|
Profit margin | -82.56 |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +254.65% upside |
Next Earnings | 6 sie 2025 |
---|
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
8 maj 2025, 19:14 UTC
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
DJ
Read
31 gru 2024, 19:15 UTC
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 15.25 USD 254.65%
High 20 USD
Low 12 USD
Based on 9 Wall Street analysts offering 12 month price targets forVerastem Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
9 ratings
9
Buy
0
Hold
0
Sell
Based on 9 analysts giving stock ratings to Verastem Inc - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$